High-potency statins are associated with reduced osteoporosis but increased fracture risk in CKD patients: a
Ping-Hsun Wu1,2,3,4, Yi-Ting Lin2,3,5, Jian-Chih Chen6,7,8
1Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Insights
High-potency statins reduced osteoporosis diagnosis in chronic kidney disease (CKD) patients but increased long-term fracture risk. This suggests a need for careful statin selection and bone health monitoring in CKD populations.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Chronic kidney disease (CKD) affects over 850 million people globally.
- CKD is linked to higher risks of cardiovascular disease and fractures.
- The impact of statin potency on bone health in CKD patients is not fully understood.
Purpose of the Study:
- To investigate the association between high-potency statins and bone health outcomes in CKD patients.
- To compare osteoporosis incidence and fracture risk in CKD patients initiating high-potency versus low-potency statins.
Main Methods:
- Retrospective cohort study of CKD stages 3-4 patients using the TriNetX US Collaborative Network.
- 1:1 propensity score matching for patients initiating high-potency (atorvastatin, rosuvastatin) or low-potency statins.
- Outcomes included new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3-12 months and beyond 12 months.
Main Results:
- High-potency statins were linked to a 20% reduction in osteoporosis diagnosis and 24.9% fewer anti-osteoporotic medication prescriptions within 3-12 months.
- No significant difference in fracture risk was observed at 3-12 months.
- Fracture risk increased by 13% beyond 12 months with high-potency statins.
Conclusions:
- High-potency statins correlate with lower osteoporosis diagnosis and anti-osteoporotic medication use in CKD stages 3-4.
- The observed increase in long-term fracture risk might stem from underdiagnosis of osteoporosis, leading to undertreatment.
- Further randomized controlled trials with bone-specific endpoints are necessary to validate these findings.
Abstract:
Chronic kidney disease patients face increased osteoporosis and fracture risk. High-potency statins were associated with lower osteoporosis incidence but also with higher long-term fracture incidence in this observational study. These findings highlight the need for tailored statin use and proactive fracture monitoring in CKD populations for optimal bone health management.
Purpose:
Chronic kidney disease (CKD) affects approximately 850 million people worldwide and is associated with increased risks of cardiovascular events and fractures. The differential effects of statin potency on bone health in CKD patients remain incompletely understood.
Methods:
This retrospective cohort study used the TriNetX US Collaborative Network to identify adults with CKD stages 3 or 4 initiating statin therapy, categorized into high-potency (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) and low-potency groups. After 1:1 propensity score matching, three primary outcomes were evaluated: new osteoporosis diagnosis, anti-osteoporotic medication initiation, and incident fractures, assessed at 3-12 months and beyond 12 months. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated using Cox and competing risk regression models.
Results:
Among 873,180 matched patients, high-potency statins were associated with a 20.0% reduction in osteoporosis diagnosis (HR 0.80; 95% CI 0.78-0.82) and 24.9% fewer anti-osteoporotic medication prescriptions (HR 0.75; 95% CI 0.73-0.78) during 3-12 months, with associations persisting beyond 12 months. Fracture risk did not differ at 3-12 months (HR 0.99; 95% CI 0.96-1.02); but increased beyond 12 months (HR 1.13; 95% CI 1.11-1.15).
Conclusions:
High-potency statins are associated with lower osteoporosis diagnosis rates and fewer anti-osteoporotic medication prescriptions in CKD stages 3 and 4. The increased long-term fracture risk may reflect a diagnostic gap wherein lower osteoporosis detection contributes to under-treatment of bone fragility. Prospective randomized controlled trials with bone-specific endpoints are warranted to confirm these findings.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Pharmacokinetics: Drug–Drug Interactions
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:24Chronic Kidney Disease II: Clinical Manifestations
01:28Chronic Kidney Disease III: Interprofessional Care